adverse effects azathioprine gene polymorphism inosine triphosphate pyrophosphatase thiopurine methyltransferase a b s t r a c t Background: Azathioprine is used as an immunosuppressant and corticosteroid-sparing agent for the treatment of several cutaneous diseases. The mutation of thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) has been reported to result in the accumulation of toxic thiopurine metabolites and to increase the adverse effects during azathioprine treatment. In the Chinese population, TPMT*3C and ITPA C94A polymorphisms have been documented. Methods: Genotyping was performed for TPMT and ITPA polymorphisms in 92 unrelated healthy volunteers and in 74 dermatology patients (46 with adverse effects and 28 without adverse effects) during azathioprine treatment. Results: Two functional polymorphisms, TPMT*3C and ITPA C94A, were detected. After analysis, ITPA C94A showed weak association with nausea/vomiting induced by azathioprine. Furthermore, we revealed that the ITPA 94 A allele was most common in patients with nausea/vomiting and developing slow-appearing adverse effects (67%), followed by patients with nausea/vomiting but not developing slow-appearing adverse effects (50%) and patients without nausea/vomiting but developing slowappearing adverse effects (25%). Conclusion: Adverse reaction to azathioprine cannot be predicted by TPMT polymorphism. However, genetic testing of ITPA polymorphism may be more important for the prediction of nausea/vomiting in Taiwanese. Currently, regular blood tests and clinical vigilance remain most important in preventing severe drug reactions during clinical use of azathioprine.
Introduction
Azathioprine, a prodrug of 6-mercaptopurine, has been used as an antileukemic, anti-inflammatory, and immunosuppressive agent to treat many debilitating skin diseases such as atopic dermatitis, autoimmune bullous disease, chronic actinic dermatitis, erythema multiforme, lichen planus, and pityriasis rubra pilaris. 1e6 However, serious adverse drug reactions (ADRs) may occur, which necessitate drug discontinuation and may result in fatality. The common ADRs include myelosuppression (neutropenia or leukopenia), gastrointestinal adverse effect (nausea/diarrhea), pancreatitis, and hepatotoxicity. The incidence is estimated to be 15e28% in patients with inflammatory bowel diseases (IBD), mainly Crohn's disease. 7e10 In a survey conducted in England, dermatologists reported that 29.1% of their patients experienced ADRs. 11 There are relatively few safety data of azathioprine in Asian dermatology patients. Azathioprine undergoes extensive metabolism after administration, which affects both its efficacy and safety. During azathioprine treatment, efficacy is not achieved in approximately 15e20% of cases and serious ADR leads to cessation of therapy in 9e28% of patients. 12 Thiopurine methyltransferase (TPMT) 13 and inosine triphosphate pyrophosphatase (ITPA) are two key enzymes ClinicalTrials.gov Identifier: NCT00525473. Conflicts of interest: The authors declare that they have no financial or nonfinancial conflicts of interest related to the subject matter or materials discussed in this article.
responsible for the metabolism of azathioprine. More than 25 TPMT polymorphisms exist (TPMT*2e28), and both TPMT and ITPA polymorphisms differ within different races. However, only 29% of leukopenic patients had TPMT mutant polymorphism. Therefore, the relationship between these two gene polymorphisms and ADR is not conclusive.
14 Polymorphisms in these two enzymes have been suggested to correlate with ARD and efficacy during azathioprine use but existing data is inconsistent. For example, the significance of ITPA polymorphism as proposed by Marinaki et al 15 was not duplicated in two subsequent studies. 16, 17 The aim of our study was to investigate the association between TMPT and ITPA polymorphisms and ADR during azathioprine treatment in dermatology patients of Han-Chinese ancestry in a tertiary referral center in Taiwan.
Methods

Study participants
We recruited 74 Han-Chinese patients with dermatology diseases in the National Taiwan University Hospital. All patients received azathioprine (Imuran 50 mg; GlaxoSmithKline, Brentford, London, UK) therapy for at least 3 months or until the appearance of ADR, which led to azathioprine discontinuation. Fifty patients were in the eczema or psoriasis group (hand eczema, foot eczema, prurigo nodularis, atopic dermatitis, erythroderma, and psoriasis vulgaris) and 24 patients were in the noneczema group (bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, dermatomyositis, and lupus erythematosus).
The initial dosage of azathioprine was based on the age, body weight, and pretreatment leukocyte counts of patients with subsequent dose escalation according to clinical efficacy and ADR. Usually an empirical daily dose of 50 mg was given first and increased to 100 mg in 2e4 weeks for patients with normal liver function and a baseline leukocyte count >6 Â 10 9 /L. A further increase to 2.5e3 mg/kg/day was given to patients with an inadequate clinical response after 6e8 weeks and with a target of leukocyte counts >4 Â 10 9 /L. The suggested monitor for hematological adverse effects was biweekly for the first 3 months and then monthly. The study protocol, approved by the institutional review committee, conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Definition of adverse effects
Hepatotoxicity was defined by serum alanine transaminase levels greater than twice the upper normal limit (50 IU/L) and resolution after withdrawal of azathioprine; pancreatitis by severe abdominal pain and serum amylase >800 IU/L. Hematotoxicity, including neutropenia, leukopenia, pancytopenia, and/or thrombocytopenia was defined according to the grading system of National Cancer Institute, United States (http://ctep.cancer.gov). 18 The slow-appearing ADRs were defined as ADRs appearing after 3-months' therapy. 19 
DNA preparation
Genomic DNA was extracted from oral swabs, which were collected from 74 patients with dermatologic diseases, using QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturers' instructions. DNA samples from 92 unrelated healthy volunteers serves as control. The isolated genomic DNAs were analyzed by agarose gel electrophoresis, quantity determined by spectrophotometry, and stored at À80 C until use.
Single nucleotide polymorphism genotyping
DNA fragments in the targeting regions of TPMT and ITPA genes were amplified using ABI 9700 (Applied Biosystems Inc., Foster City, CA, USA) PCR machine employing two pairs of forward and reverse primers. We studied the polymorphisms TPMT*2 (exon 4, G238C), TPMT*3B (exon 6, G460A and C474T), TPMT*3C (exon 9, A719G), TPMT*4 (intron 8, G/A), TPMT*7 (exon 9, T681G), TPMT*8 (exon 9, G644A), ITPA exon 2 C94A and ITPA intron 2 A/C. The fragments of PCR products were sequenced by ABI 3700 automatic sequencer according to the manufacturer's protocol. The sequence data were analyzed by Polyphred software (version 6.18, 2009, the University of Washington, Seattle, Washington, US) to identify the potential candidate single nucleotide polymorphisms (SNPs). The identified potential SNPs were manually checked to ensure the presence of a true SNP and the allele of each individual. Three independent manual confirmations were performed for all the sequence data and only when all three were identical were data subjected to the subsequent statistical analysis (Appendix 1).
Statistical analysis
All association analyses between adverse drug reactions and polymorphisms were tested by the Chi-squared test or Fisher's exact test. Odds ratios and 95% confidence intervals were calculated from contingency tables. Statistical analysis was performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The demographic and clinical characteristics of the 74 patients are shown in Table 1 . The mean age in ADR group was slightly greater than in the non-ADR group without statistical significance. The initial dosage of azathioprine was not different between the two patients groups. TPMT*3C and ITPA C94A polymorphism
We investigated the frequencies of TPMT and ITPA genes alleles in 92 Han-Chinese volunteers in Taiwan. Among the nine SNPs, only three were detected by our screening in Taiwanese population. Two SNPs, rs1142345 (also known as TPMT*3C) and rs2842934, were in the TPMT gene, and one SNP, rs41320251 (also known as ITPA C94A) was in the ITPA gene. The exonic SNPrs2842934 did not cause amino acid change in the TPMT gene. Thus, genotyping for TPMT*3C and ITPA C94A polymorphisms was performed in patients treated with azathioprine.
Association analysis
Neither TPMT*3C nor ITPA C94A was associated with azathioprine overall toxicity ( Table 2 ). The association analysis using cooccurring genotypes of TPMT*3C and ITPA C94A also did not show statistical significance ( Table 2 ). The overall toxicity was further divided into four ADR groups including hematopoietic toxicity, nausea/vomiting, hepatotoxicity, and others. Others included tiredness, rash, itch, diarrhea, and arthralgia. Neither TPMT*3C nor ITPA C94A showed association to these four groups of toxicities ( Table 3 ). The comparisons between with and without single ADR were also performed. ITPA C94A showed weak association to nausea/vomiting in the genotypic test (p ¼ 0.076; Table 3 ) and in the allelic test (p ¼ 0.046). Odds ratio analysis revealed ITPA CA þ AA genotypes were risk factors for other adverse effects with a marginal statistical significance (p ¼ 0.06). The odds ratio for co-occurring genotypes of TPMT*3C and ITPA C94A (reference co-occurring genotype TPMT*3C AA and ITPA C94A CC) genotype showed carriers with TPMT*3C and/or ITPA 94A allele had risk to developing nausea/vomiting, odds ratio ¼ 2.71 and p ¼ 0.086 (Table 3) .
As shown in Table 4 , ITPA 94 A allele carriers were most common in patients with nausea/vomiting and developing slowappearing adverse effects (67%), followed by patients with nausea/vomiting but not developing slow-appearing adverse effects (50%), and patients without nausea/vomiting but developing slow-appearing adverse effects (25%). Twelve patients with nausea/ vomiting kept the same dosage of azathioprine, two patients received tapering dosage of azathioprine and one patient discontinued the usage of azathioprine. However, further analysis of TPMT*3C was difficult due to the small sample size.
Discussion
ADR from azathioprine may be under reported in Taiwan. 20 Although pretherapeutic screening of TPMT and ITPA polymorphisms has been recommended in patients treated with azathioprine in recent guidelines, 21 a major portion of hematopoietic toxicity and/or hepatotoxicity is not predictable or cannot be avoided by genetic testing. The importance of TPMT and ITPA polymorphism seems to differ among Eastern versus Western people, and even in Asians.
Azathioprine is a prodrug of 6-mercaptopurine (6-MP). The initial success in kidney transplantation in 1962 broadened its clinical applications thereafter. In dermatology, it is used for the treatment of various dermatoses. However, a high unresponsive rate and a wide range of ADR of azathioprine exist. Nausea and malaise are the most frequent dose-dependent ADR. Myelosuppression is also a dose-dependent ADR and was experienced in 5% of patients with IBD. 22 After oral administration, azathioprine is absorbed almost completely by the gut. It is then converted nonenzymatically to 6-MP and then undergoes complex metabolism by three key competing enzymes. TPMT converts azathioprine to form inactive methyl-thiopurine metabolites. 13 At least 28 TPMT allele polymorphisms have has been identified, with TPMT*2, *3A, and *3C accounting for over 95% of the TPMT deficiency. 23 TPMT*3A (G460A and A719G) is frequently expressed in white Americans and SouthWest Asians. 24 TPMT*3C (A719G) is the only TPMT variant in the Chinese population 25 and is also found in Ghanaian, Korean, and Japanese populations. The other variants are rare 26 and may represent mutation rather than true polymorphism. TPMT activity can be categorized into high (88.6%, homozygous for wild-type alleles, TPMT *1/*1), intermediate (11.1%, heterozygous for mutant allele, TPMT *1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4), and undetectable (0.3%, homozygous or compound heterozygous for mutant alleles, TPMT *3A/*3A, *2/*3A, *3C/*3A, *3C/*4, *3C/*2, *3A/*4).
27,28
Although a systematic review showed that the enzymatic test is more likely to detect cases at risk for azathioprine toxicity because a decrease in activity can also be caused by any known or unknown mutations or external confounding factors (e.g., drug interactions, blood transfusions), the enzymatic tests are limited by recent blood transfusions, other medications, alcohol, and food. 29 A high concordance (98.4%) between TPMT genotypes and phenotypes has been reported. 30 Thus genotyping offers a more convenient way in clinical studies. TPMT*3C (719A > G) is the most common variant allele in Taiwanese with allelic frequencies from 0.12% to 1.28%. 31 TPMT*3C allele in our series is all heterozygous TPMT *1/*3C (TPMTH/TPMTL, TPMT A/G), which is compatible with the results in the Japanese group (0.8e1.6% and all heterozygous) and the enzyme activity of TPMT *1/*3C is about 25% lower than that of the wild-type. 32 Low or absent TPMT activity may be correlated with risk of acute severe neutropenia, due to excessive accumulation of intercellular 6-thioguanine nucleotides (an active metabolite), when individuals were exposed to standard doses of azathioprine.
33
Most studies on the correlation between TPMT polymorphism and ARD are in patients with IBD, mainly in Westerners in which the TPMT gene predicts hematological ADRs, 34 in 5e10% of patients treated with thiopurine drugs. 8 Other studies have demonstrated that only 29% of leukopenic patients had mutant polymorphisms 14 and indicated that only one-third of myelosuppressive episodes can be attributed to genetic polymorphism. 35 The remaining causes may be mediated by immune mechanisms or by other variables affecting the metabolism of the drug. 6 TPMT activity does not usually predict azathioprine-induced hepatotoxicity or gastrointestinal upset. 36 TPMT activity itself varies among races and it has been reported that the enzyme activity of TPMT in the Japanese population is about 50% and is approximately 70% lower 37, 38 than in Jewish and white Americans, respectively. Therefore, screening for the TPMT gene mutation alone may be inappropriate for predicting azathioprine/6-MP-induced adverse reactions. 39 More recently, ITPA deficiency has also been associated with thiopurine toxicity. ITPA converts 6-thio inosine triphosphate to phosphorylated 6-thio IMP, an intermediate metabolite of azathioprine/6-MP. When ITPA activity is reduced or defective, toxic 6-thio inosine triphosphate accumulates and induces adverse reactions, such as myelotoxicity. Five functional SNPs of the ITPA gene have been reported. 40 ITPA enzyme activity in red blood cells is reportedly zero in individuals with the homozygous 94C > A missense mutation (Pro to Thr) in the open reading frame, and is markedly lower (22.5e27% of the activity) in those with heterozygous mutations. Homozygotes for the other functional polymorphism in intron 2 (IVS2 þ 21A > C) and compound heterozygous subjects express about 30% of the wild-type median value of enzyme activity.
41e43
The frequency of the 94C > A polymorphism is higher in Asian populations (11e23%), than in Caucasian populations (5e7%), 44 and is likely to be the major ITPA polymorphism in the Chinese population. 45 In our series, the allele frequency of the 94C > A polymorphism is 0.1648, similar to 0.155 in the Japanese population. 42 This frequency is 2.75 fold higher than in Caucasians (0.06), 41 showing that ITPA gene mutation is more important in HanChinese individuals whereas TPMT gene mutation is more frequent in Caucasians. Our result showed a significant association between ITPA 94C > A homozygote and azathioprine-related gastrointestinal toxicity and flu-like symptoms, which is similar to another Chinese study. 45 However, contradictory results also exist.
15e17,46
In this study, ITPA C94A showed weak association to nausea/ vomiting induced by azathioprine and TPMT*3C and/or ITPA 94 A alleles were potential risk to developing nausea/vomiting after azathioprine treatment. The results suggest patients with both wildtypes of TPMT and ITPA were less likely to develop ADR. Dose lowering or even discontinuation was usually performed with the occurrence of fast-appearing ADR such as nausea and vomiting, and it may prevent the onset of slow-appearing adverse effects, including hematopoietic toxicity and hepatotoxicity as seen in our study.
Various treatment guidelines for azathioprine have advocated pretherapeutic testing of TPMT status. 35, 47, 48 However, pretreatment tests are still controversial due to the following reasons. First, there is a lack of direct evidence that TPMT or ITPA testing would decrease myelotoxicity-specific mortality. Second, regular complete blood counts measurement alone may be sufficient to early detect severe myelotoxicity. Third, the regimens of azathioprine vary between different specialties and different disease, which would cause variable results in different studies. Fourth, adverse reactions occurred in the presence of wild type TPMT and ITPA genes in more than 50% of patients. 49 Fifth, mutations in other enzymes (such as HPRT1), drug interactions, concurrent infections, and immune-mediated drug reactions could lead to toxicity. Sixth, the low prevalence of homozygotes means that current evidences are underpowered to prove the effectiveness of pretesting for detection of patients at risk. Seventh, dosing according to the results of TPMT or ITPA status, may lead to underdosing of thiopurine and reduce clinical effectiveness. 53, 54 Major drawbacks of our study are the small sample size and the lack of concurrent testing for enzymatic activity of TPMT and ITPA. At least 56 AZA-intolerable patients and 280 AZA-tolerable patients were required in our study to detect the significant differences of TPMT*3C and ITPAC94A polymorphism between AZA-treated Taiwanese patients with and without ADR. Heterogeneous diseases entities are included in the study, which will affect the dosing of azathioprine. Azathioprine is usually used as monotherapy in eczema, whereas in autoimmune and immunobullous diseases, it is used as a steroid sparing agent in our series. 55 However, concurrent medication is relatively simple in our series and is free of drugs known to interact with azathioprine, such as 5-aminosalicylic acid which is often used for the treatment of IBS.
In conclusion, similar to the Japanese population, adverse reaction to azathioprine cannot be predicted by TPMT polymorphism but genetic testing of ITPA polymorphism may be more important for the prediction of nausea/vomiting in Taiwanese. However, prior to the discovery of new genomic polymorphisms or other nongenomic factors, regular blood tests and clinical vigilance remain most important in preventing a severe drug reaction during the clinical use of azathioprine.
